Overview of biomarkers in disease, drug discovery and development

Drug Discovery World

Volumn 6, Issue 2, 2005, Pages 21-30

  Naylor, Stephen ^a,b,c,d  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c MAYO CLINIC   (United States)

^d MEDICAL RESEARCH COUNCIL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; DRUG;

BIOTECHNOLOGY; DIAGNOSTIC PROCEDURE; DRUG EFFICACY; DRUG INDUSTRY; DRUG RESEARCH; DRUG SYNTHESIS; HUMAN; IMMUNOHISTOCHEMISTRY; MEDICAL DECISION MAKING; PHYSICAL DISEASE; PRODUCTIVITY; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; VALIDATION PROCESS;

EID: 17744365409     PISSN: 14694344     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (26)

1. GenomeWeb Staff Reporter. Pharma spent $38.8B on R&D in 2004, a 12% jump; breakdown on genome spending soon. GenomeWeb (www.genomeweb.com) 2/18/05.
2. Booth, B and Zemmel, R. Prospects for productivity. Nat. Rev. Drug Dis. 3: 451-456 (2004).
3. FDA Federal Drug Administration (FDA), Department of Human Health and Services. Challenge and opportunity on the critical path to new medical products. April 2004 (www.fda.gov/oc/initiatives/criticalpath/).
4. DiMasi, JA, Hansen, RW and Grabowski, HG.The price of innovation: New estimates of drug development costs. J. Health Econ. 22: 151-185 (2003).
5. Bains, W. Failure rates in drug discovery and development: will we ever get any better? Drug Discovery World 5: 9-18 (2004).
6. Naylor, S. Systems Biology, information, disease and drug discovery. Drug Discovery World 6: 23-33 (2005).
7. Mattera, MD. Memo from the editor. A way to curb healthcare costs? Medical Economics December 3rd, 2004, (www.memag.com/memag/article).
8. Morel, N et al. Introduction to Systems Biology-A new approach to understanding disease and treatment. Mayo Clin. Proc. 79: 651-658 (2004).
9. Frank, R and Hargreaves, R. Clinical biomarkers in drug discovery and development. Nature Drug Discov. 2: 566-580 (2003).
10. Naylor, S. Biomarkers: Current perspectives and future prospects. Expert Rev. Mol. Diagn. 3:525-529 (2003).
11. Zolg, JW and Langen, H. How industry is approaching the search for new diagnostic markers and biomarkers. Mol. Cell. Proteomics. 3:345-354 (2004).
12. Colburn,W.A. Biomarkers in drug discovery and development. From target identification through drug marketing. J. Clin. Pharmacol. 43:329-341 (2003).
13. Trull,AK et al (Eds). Biomarkers of Disease. An evidence-based approach. Cambridge University Press, Cambridge, UK. 2002.
14. Biomarker Definitions Working Group. Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 69: 89-95 (2002).
15. Temple, R. Are surrogate markers adequate to address cardiovascular disease drugs? JAMA 282: 790-795 (1998).
16. Lathia, CD. Biomarkers and surrogate endpoints: How and when they might impact drug development. Disease Markers 18: 83-90 (2002).
17. Cambridge Healthtech; www.geno micglossaries.com/content/biomarkers.asp
18. De Meyer, G and Shapiro, E Biomarker development:The road to clinical utility. Current Drug Discovery May: 23-27 (2003).
19. Ferber, G. Biomarkers and proof of concept. Methods Find. Exp. Clin. Pharmacol. 24 (Supplement C): 35-40 (2002).
20. Naylor, S and Cavanagh, J. Status of systems biology-does it have a future? Drug Discovery Today-Biosilico 2: 171-174 (2004).
21. Schena, M et al. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science 270: 467-470 (1995).
22. Hood, L.A personal view of molecular technology and how it has changed biology. J. Protome Res. 1: 399-409 (2002).
23. Ilyin, SE, Belkowski, SM and Plata-Salaman, CR. Biomarker discovery and validation: technologies and integrative approaches. Trends Biotechnol. 22: 411-416 (2004).
24. Ilyin, SE et al. Functional informatics: convergence and integration of automation and bioinformatics. Pharmacogenomics 5: 721-730.
25. Neumann, E and Thomas, J. Knowledge assembly for the life sciences. Drug Discov. Today (Supplement) 7: S160-S162 (2002).
26. Rubenstein, K. Post-Genomic Biomarkers: Revolutionizing Drug Development and Diagnostics. (2003) DM&D Publications, Westborough, MA, USA. (http://www.drugand market.com).